Servicios Personalizados
Revista
Articulo
Indicadores
Citado por SciELO
Links relacionados
Similares en SciELO
Compartir
Medicina (Buenos Aires)
versión impresa ISSN 0025-7680versión On-line ISSN 1669-9106
Resumen
RAIMONDO, Nélida et al. Biosimilares: consenso de expertos de la Sociedad Latinoamericana de Psoriasis (SOLAPSO) en Argentina. Medicina (B. Aires) [online]. 2018, vol.78, n.4, pp.272-281. ISSN 0025-7680.
With the appearance of biological treatments, therapeutics has changed in many rheumatological, dermatological and oncological diseases. Due to the high cost of these biological medicaments and the expiration of patents, the pharmacological industry develops biosimilars, drugs that are a version (copy) of the substance of the original biological medicine, with the aim of facilitating access to these treatments. These biosimilars are prepared according to the specific requirements of regulatory bodies in terms of quality, efficacy and safety, and must be shown they are comparable to the reference product. This paper reviews the international and national regulatory framework, the controversies surrounding biosimilars, and presents the position of a group of experts regarding the use of biosimilars.
Palabras clave : Biological; Biosimilar; Consensus; Psoriasis.